Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

227 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ribociclib plus letrozole versus chemotherapy for postmenopausal women with hormone receptor-positive, HER2-negative, luminal B breast cancer (CORALLEEN): an open-label, multicentre, randomised, phase 2 trial.
Prat A, Saura C, Pascual T, Hernando C, Muñoz M, Paré L, González Farré B, Fernández PL, Galván P, Chic N, González Farré X, Oliveira M, Gil-Gil M, Arumi M, Ferrer N, Montaño A, Izarzugaza Y, Llombart-Cussac A, Bratos R, González Santiago S, Martínez E, Hoyos S, Rojas B, Virizuela JA, Ortega V, López R, Céliz P, Ciruelos E, Villagrasa P, Gavilá J. Prat A, et al. Among authors: fernandez pl. Lancet Oncol. 2020 Jan;21(1):33-43. doi: 10.1016/S1470-2045(19)30786-7. Epub 2019 Dec 11. Lancet Oncol. 2020. PMID: 31838010 Clinical Trial.
p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma.
Rey MJ, Fernández PL, Jares P, Muñoz M, Nadal A, Peiró N, Nayach I, Mallofré C, Muntané J, Campo E, Estapé J, Cardesa A. Rey MJ, et al. Among authors: fernandez pl. J Pathol. 1998 Mar;184(3):265-71. doi: 10.1002/(SICI)1096-9896(199803)184:3<265::AID-PATH8>3.0.CO;2-8. J Pathol. 1998. PMID: 9614378
Substance P autocrine signaling contributes to persistent HER2 activation that drives malignant progression and drug resistance in breast cancer.
Garcia-Recio S, Fuster G, Fernandez-Nogueira P, Pastor-Arroyo EM, Park SY, Mayordomo C, Ametller E, Mancino M, Gonzalez-Farre X, Russnes HG, Engel P, Costamagna D, Fernandez PL, Gascón P, Almendro V. Garcia-Recio S, et al. Among authors: fernandez pl, fernandez nogueira p. Cancer Res. 2013 Nov 1;73(21):6424-34. doi: 10.1158/0008-5472.CAN-12-4573. Epub 2013 Sep 12. Cancer Res. 2013. PMID: 24030979 Free article.
227 results